PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33733088-9 2021 5 muM of ruthenium red was used as an efficient blocker of ionic current through TRPV4 channels. Ruthenium Red 9-22 transient receptor potential cation channel subfamily V member 4 Homo sapiens 81-86 24911002-7 2015 GSK- and PMA-induced Ca(2+) elevations were inhibited by RN-1734 and ruthenium red, which selectively target TRPV4 in mature endothelium. Ruthenium Red 69-82 transient receptor potential cation channel subfamily V member 4 Homo sapiens 109-114 21938744-6 2012 Blocking of TRPV4 by ruthenium red abolished calcium influx as well as RVD, identifying TRPV4 as a necessary component in volume regulation. Ruthenium Red 21-34 transient receptor potential cation channel subfamily V member 4 Homo sapiens 12-17 34562506-7 2021 When HYPX exposure and TRPV4 agonist (GSK1016790A)-induced TRPV4 activity were inhibited by the treatment of ruthenium red or MLT, the increase of mROS, lipid peroxidation, apoptosis, Zn2+ concentrations, TRPV4, caspase -3, caspase -9, Bax, and Bcl-2 expressions were restored via upregulation of reduced glutathione, glutathione peroxidase and total antioxidant status. Ruthenium Red 109-122 transient receptor potential cation channel subfamily V member 4 Homo sapiens 23-28 34562506-7 2021 When HYPX exposure and TRPV4 agonist (GSK1016790A)-induced TRPV4 activity were inhibited by the treatment of ruthenium red or MLT, the increase of mROS, lipid peroxidation, apoptosis, Zn2+ concentrations, TRPV4, caspase -3, caspase -9, Bax, and Bcl-2 expressions were restored via upregulation of reduced glutathione, glutathione peroxidase and total antioxidant status. Ruthenium Red 109-122 transient receptor potential cation channel subfamily V member 4 Homo sapiens 59-64 34562506-7 2021 When HYPX exposure and TRPV4 agonist (GSK1016790A)-induced TRPV4 activity were inhibited by the treatment of ruthenium red or MLT, the increase of mROS, lipid peroxidation, apoptosis, Zn2+ concentrations, TRPV4, caspase -3, caspase -9, Bax, and Bcl-2 expressions were restored via upregulation of reduced glutathione, glutathione peroxidase and total antioxidant status. Ruthenium Red 109-122 transient receptor potential cation channel subfamily V member 4 Homo sapiens 205-210 34989943-12 2022 TRPV4 is activated by the treatments of GSK1016790A (GSK), although it is inhibited by a nonspecific inhibitor (ruthenium red, RuRe). Ruthenium Red 112-125 transient receptor potential cation channel subfamily V member 4 Homo sapiens 0-5 31778738-6 2020 Vanilloid transient potential (TRPV) channel inhibitor Ruthenium Red, but not a voltage-dependent calcium channel (VDCC) inhibitor nifedipine, efficiently stunted Ca2+ entry, and comparable abrogation was reproduced in cells treated with TRPV4-selective inhibitor RN-1734 or transfected with TRPV4-specific siRNA. Ruthenium Red 55-68 transient receptor potential cation channel subfamily V member 4 Homo sapiens 238-243 31778738-6 2020 Vanilloid transient potential (TRPV) channel inhibitor Ruthenium Red, but not a voltage-dependent calcium channel (VDCC) inhibitor nifedipine, efficiently stunted Ca2+ entry, and comparable abrogation was reproduced in cells treated with TRPV4-selective inhibitor RN-1734 or transfected with TRPV4-specific siRNA. Ruthenium Red 55-68 transient receptor potential cation channel subfamily V member 4 Homo sapiens 292-297 26413835-4 2016 Using calcium imaging, we show that AQP-mediated fast swelling kinetics also significantly increases the amplitude of calcium transients inhibited by Gadolinium and Ruthenium Red, two inhibitors of the transient receptor potential vanilloid 4 (TRPV4) channels, and prevented by removing extracellular calcium. Ruthenium Red 165-178 transient receptor potential cation channel subfamily V member 4 Homo sapiens 202-242 31685769-2 2019 TRPV4 antagonists ruthenium red and HC-067047 significantly blocked increased urinary volume after intragastric administration of water and 4alpha-PDD-induced diuresis. Ruthenium Red 18-31 transient receptor potential cation channel subfamily V member 4 Homo sapiens 0-5 30761248-8 2019 In addition, TRPV4 was activated by hypotonic solutions (220 m Osm), and this effect was abolished by ruthenium red. Ruthenium Red 102-115 transient receptor potential cation channel subfamily V member 4 Homo sapiens 13-18 29664963-3 2018 Mechanical stretch increased intracellular Ca2+ influx and induced release of pro-inflammatory cytokines in lung epithelial cells that was partially blocked by about 30% with the selective TRPV4 inhibitor GSK2193874, but nearly completely blocked with the pan-calcium channel blocker ruthenium red, suggesting the involvement of more than one calcium channel in the response to mechanical stress. Ruthenium Red 284-297 transient receptor potential cation channel subfamily V member 4 Homo sapiens 189-194 26413835-4 2016 Using calcium imaging, we show that AQP-mediated fast swelling kinetics also significantly increases the amplitude of calcium transients inhibited by Gadolinium and Ruthenium Red, two inhibitors of the transient receptor potential vanilloid 4 (TRPV4) channels, and prevented by removing extracellular calcium. Ruthenium Red 165-178 transient receptor potential cation channel subfamily V member 4 Homo sapiens 244-249 23288842-7 2013 Removal of extracellular Ca(2+) and treatment with the TRPV4 antagonists Ruthenium Red or HC067047 prevented the sustained response. Ruthenium Red 73-86 transient receptor potential cation channel subfamily V member 4 Homo sapiens 55-60 26294342-5 2015 KEY RESULTS: In mesenteric arteries, endothelium-dependent relaxation to both 2-AG and GSK was attenuated by structurally distinct TRPV4 antagonists, HC067047, RN1734 and ruthenium red. Ruthenium Red 171-184 transient receptor potential cation channel subfamily V member 4 Homo sapiens 131-136 24920677-5 2014 Blockade of TRPM7 by 2-APB or TRPV4 by Ruthenium red inhibited shear stress-induced rise in [Ca(2+)]cyt in normal and IPAH-PASMC, while activation of TRPM7 by bradykinin or TRPV4 by 4alphaPDD induced greater increase in [Ca(2+)]cyt in IPAH-PASMC than in normal PASMC. Ruthenium Red 39-52 transient receptor potential cation channel subfamily V member 4 Homo sapiens 30-35 24504097-3 2014 As predicted, transient receptor potential vanilloid 4 activation in the human airway produces contractions that are blocked by the nonselective transient receptor potential channel blocker ruthenium red. Ruthenium Red 190-203 transient receptor potential cation channel subfamily V member 4 Homo sapiens 14-54 18684885-9 2008 In the presence of the TRPV4-selective inhibitor ruthenium red, osmolality-induced ATP release was blocked by 73% (56.4+/-19.9 vs. 8.8+/-2.3 pmol/mg protein; n=6; P<0.03). Ruthenium Red 49-62 transient receptor potential cation channel subfamily V member 4 Homo sapiens 23-28 22327830-9 2012 Whereas the TRPV1 agonist capsaicin (CAP) (5-20 muM) -induced Ca(2+) transients were blocked by capsazepine (CPZ) (10 muM), the TRPV4 activator 4alpha-PDD (10 muM) -induced Ca(2+) increases were reduced by ruthenium-red (RuR) (20 muM). Ruthenium Red 206-219 transient receptor potential cation channel subfamily V member 4 Homo sapiens 128-133 20064552-7 2010 Blockers of TRPV4 channels (Gd(3+) 500 microM; Ruthenium red 1 microM) increased the viability of astrocytes following MCS or BSO treatments, consistent with the expression pattern of these channels. Ruthenium Red 47-60 transient receptor potential cation channel subfamily V member 4 Homo sapiens 12-17 21339821-4 2011 GSK101 (10 nM) causes a TRPV4 specific Ca(2+) influx in HeLa-TRPV4 cells, but not in control transfected cells, which can be inhibited by ruthenium red and Ca(2+)-free medium more significantly at the early stage of the activation rather than the late stage, reflecting apparent partial desensitization. Ruthenium Red 138-151 transient receptor potential cation channel subfamily V member 4 Homo sapiens 24-29 21339821-4 2011 GSK101 (10 nM) causes a TRPV4 specific Ca(2+) influx in HeLa-TRPV4 cells, but not in control transfected cells, which can be inhibited by ruthenium red and Ca(2+)-free medium more significantly at the early stage of the activation rather than the late stage, reflecting apparent partial desensitization. Ruthenium Red 138-151 transient receptor potential cation channel subfamily V member 4 Homo sapiens 56-66 15075247-7 2004 The 4-alphaPDD-induced Ca(2+) response was inhibited by ruthenium red (1 microM), a known TRPV4 inhibitor, but not by capsazepine (1 microM), a TRPV1 antagonist, indicating that 4-alphaPDD-induced Ca(2+) response is mediated by TRPV4. Ruthenium Red 56-69 transient receptor potential cation channel subfamily V member 4 Homo sapiens 90-95 17068482-4 2007 4Alpha-phorbol 12,13-didecanone, an activator of TRPV4, accelerated barrier recovery, whereas ruthenium red, a blocker of TRPV4, delayed barrier recovery. Ruthenium Red 94-107 transient receptor potential cation channel subfamily V member 4 Homo sapiens 122-127 12093812-2 2002 TRPV4 is characterized by both inward and outward rectification, voltage-dependent block by Ruthenium Red, a moderate selectivity for divalent versus monovalent cations, and an Eisenman IV permeability sequence. Ruthenium Red 92-105 transient receptor potential cation channel subfamily V member 4 Homo sapiens 0-5